# Secondary Progressive Multiple Sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis

> 2 upcoming FDA catalysts in secondary Progressive Multiple Sclerosis: orelabrutinib (ZBIO) on June 2030 (primary completion); orelabrutinib (ZBIO) on Jun to Sep 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2026 | [Orelabrutinib trial start](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "The Company also expects to initiate a global Phase 3 trial of orelabrutinib in patients with Secondary Progressive Multiple Sclerosis ("SPMS") in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_8k.htm)) |
| September 17, 2026 | [Foralumab primary completion](https://sec-api.dev/pdufa/foralumab) | TLSA | Secondary Progressive Multiple Sclerosis | completed | "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292923)) |
| Sep to Dec 2026 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA | Secondary Progressive Multiple Sclerosis | scheduled | "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292923)) |
| June 2030 | [Orelabrutinib primary completion](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07299019)) |
| Jun to Sep 2030 | [Orelabrutinib topline data readout](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07299019)) |

## Drugs

- [Orelabrutinib](https://sec-api.dev/pdufa/orelabrutinib) (ZBIO)
- [Foralumab](https://sec-api.dev/pdufa/foralumab) (TLSA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Secondary Progressive Multiple Sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis

```bibtex
@misc{secapidev_indications_secondary_progressive_multiple_sclerosis_20261116,
  title        = {Secondary Progressive Multiple Sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_secondary_progressive_multiple_sclerosis_20261116","title":"Secondary Progressive Multiple Sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
